Abstract:Abnormal gene alternative splicing (AS) events are strongly associated with cancer progression. Here, we summarize AS events that contribute to the development of drug resistance and classify them into three categories: alternative cis-splicing (ACS), alternative trans-splicing (ATS), and alternative back-splicing (ABS). The regulatory mechanisms underlying AS processes through cis-acting regulatory elements and trans-acting factors are comprehensively described, and the distinct functions of spliced variants, including linear spliced variants derived from ACS, chimeric spliced variants arising from ATS, and circRNAs generated through ABS, are discussed. The identification of dysregulated spliced variants, which contribute to drug resistance and hinder effective cancer treatment, suggests that abnormal AS processes may together serve as a precise regulatory mechanism enabling drug-resistant cancer cell survival or, alternatively, represent an evolutionary pathway for cancer cells to adapt to changes in the external environment. Moreover, this review summarizes recent advancements in treatment approaches targeting AS-associated drug resistance, focusing on cis-acting regulatory elements, trans-acting factors, and specific spliced variants. Collectively, gaining an in-depth understanding of the mechanisms underlying aberrant alternative splicing events and developing strategies to target this process hold great promise for overcoming cancer drug resistance.

Mechanisms of non-coding RNA-modulated alternative splicing in cancer

The interplay between non-coding RNAs and alternative splicing: from regulatory mechanism to therapeutic implications in cancer

Long non-coding RNAs are involved in alternative splicing and promote cancer progression

Dysregulation Of Long Non-Coding Rna In Breast Cancer: An Overview Of Mechanism And Clinical Implication

The crosstalk between alternative splicing and circular RNA in cancer: pathogenic insights and therapeutic implications

Alternative splicing and cancer: a systematic review

Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics

The role of alternative splicing in human cancer progression.

Epigenetic Regulation of Alternative Splicing.

Alternative splicing of mRNA in colorectal cancer: new strategies for tumor diagnosis and treatment

RNA Structures in Alternative Splicing and Back‐splicing

Splicing factors: Insights into their regulatory network in alternative splicing in cancer

Alternative Splicing in Myeloid Malignancies

Post-transcriptional Regulation of Long Noncoding RNAs in Cancer

Opportunities and methods for studying alternative splicing in cancer with RNA-Seq.

Significance of Alternative Splicing in Cancer Cells.

Overcoming cancer drug-resistance calls for novel strategies targeting abnormal alternative splicing

Genome-wide identification of cancer-specific alternative splicing in circRNA

Roles and mechanisms of alternative splicing in cancer — implications for care

RNA splicing dysregulation and the hallmarks of cancer

Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.